In this study, we demonstrated that the tryptophan catabolism pathway TDO2-Kyn-AhR maintains the survival of ADT-induced dormant prostate cancer cells and promotes the recurrence and aggressive growth of CRPC cells (Fig. 6). This evidence concerns the gene AHR and prostate carcinoma.